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Background: Introduction of effective point-of-care devices for use in medical diagnostics is part of strategies to
combat accelerating health-care costs. Molecular motor driven nanodevices have unique potentials in this regard
due to unprecedented level of miniaturization and independence of external pumps. However motor function has
been found to be inhibited by body fluids.
Results: We report here that a unique procedure, combining separation steps that rely on antibody-antigen
interactions, magnetic forces applied to magnetic nanoparticles (MPs) and the specificity of the actomyosin bond,
can circumvent the deleterious effects of body fluids (e.g. blood serum). The procedure encompasses the following
steps: (i) capture of analyte molecules from serum by MP-antibody conjugates, (ii) pelleting of MP-antibody-analyte
complexes, using a magnetic field, followed by exchange of serum for optimized biological buffer, (iii) mixing of
MP-antibody-analyte complexes with actin filaments conjugated with same polyclonal antibodies as the magnetic
nanoparticles. This causes complex formation: MP-antibody-analyte-antibody-actin, and magnetic separation is
used to enrich the complexes. Finally (iv) the complexes are introduced into a nanodevice for specific
binding via actin filaments to surface adsorbed molecular motors (heavy meromyosin). The number of actin
filaments bound to the motors in the latter step was significantly increased above the control value if protein
analyte (50–60 nM) was present in serum (in step i) suggesting appreciable formation and enrichment of the
MP-antibody-analyte-antibody-actin complexes. Furthermore, addition of ATP demonstrated maintained heavy
meromyosin driven propulsion of actin filaments showing that the serum induced inhibition was alleviated.
Detailed analysis of the procedure i-iv, using fluorescence microscopy and spectroscopy identified main
targets for future optimization.
Conclusion: The results demonstrate a promising approach for capturing analytes from serum for subsequent
motor driven separation/detection. Indeed, the observed increase in actin filament number, in itself, signals
the presence of analyte at clinically relevant nM concentration without the need for further motor driven
concentration. Our analysis suggests that exchange of polyclonal for monoclonal antibodies would be a
critical improvement, opening for a first clinically useful molecular motor driven lab-on-a-chip device.
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In the recent decades, healthcare costs have soared
throughout the industrialized world and this development
is predicted to continue, e.g. with the costs reaching 30%
of the gross domestic product in the US 2035 (compared
to 15% in 2007 and 5% in 1960 [1]) Together with
environmental and climate issues this is one of the biggest
challenges facing industrialized nations. The efforts to* Correspondence: alf.mansson@lnu.se
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reproduction in any medium, provided the ordevelop new biosensing devices that are cheaper, faster,
and more accurate should be viewed in this context.
Such devices would allow detection of diseases and
environmental changes at an early stage with increasing
chances for interventions at a low cost.
Of interest in this connection are lab-on-a-chip devices
[2-4] where miniaturized chips, can perform a series of
analyses and be used at the point of care or in the field
rather than in a centralized laboratory. However, while
appreciable progress has been made towards such
devices [3] they often require expensive and bulkyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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drive microfluidics flow demand increasingly more power
the greater the miniaturization [5] and the manufacturing
of the chip components becomes increasingly challenging
and expensive. To overcome these problems it has been
proposed that biological molecular motors, with their
inherent extensive miniaturization, biodegradability and
self-propelling features, may be used to transport analytes
e.g. from recognition to detection chambers, achieving
separation, concentration as well as certain forms of
detection [6-8]. Several important steps towards a
functional molecular motor driven diagnostic device
have also been realized (reviewed in [8-13]) such as: (i)
attachment of antibodies to cytoskeletal microtubule
[14] and actin filament [15] shuttles, followed by
molecular motor-driven transportation of analytes (viruses,
protein antigens etc.) bound to the antibodies, (ii) nano/
microfabrication of devices for guided transportation of
the motor propelled shuttles to concentrate analytes at a
detector site [6,7,16-18] and (iii) long-term storage of
ready-to-use devices without loss of activity [19-21].
Despite the above developments, challenges remain
before a commercially viable molecular motor driven
device is realized. Particularly, we showed recently [22]
that complex fluid environments, such as blood plasma,
blood serum and cell lysates may have deleterious effects
on molecular motor driven propulsion of both actin
filaments and microtubules, unless the samples are
diluted > 100 times. These problems are essential to
overcome since extensive sample dilution is highly
undesirable in high-sensitivity detection. Separation of
targeted molecules from biological fluids, using magnetic
microparticles with antibodies immobilized on their
surface, may be useful in this connection. Such separation
is a technique of growing importance in biosensing [23,24]
and more recently, also magnetic nanoparticles have been
used for similar purposes [25].
Here we utilize magnetic nanoparticles to investigate
whether an approach with a magnetic pre-separation
step is a way forward in alleviating the deleterious
effects of complex fluid environments on motor driven
diagnostics devices. Our results are promising, showing
effective exchange of the deleterious fluid components
for optimized biological buffers thus enabling subsequent
motor driven transportation. We also found evidence
that the presence of antigen (analyte) cross-links
magnetic particles and actin filaments to an appreciable
degree if both particles and filaments are conjugated
with polyclonal antibodies against the analyte in question.
Whereas the method is potentially useful already at
the present stage of development, our microscopy and
spectroscopy based analysis suggests that there is
appreciable room for further optimization as discussed in
some detail.Results and discussion
Molecular motor-based proof-of-principle nanodevices
for diagnostics applications [6,7,16,26] have been tested
in optimized biological buffers but not in complex fluid
environments, such as blood serum, encountered in a
real device. This is a concern as we recently [22] found
that both actomyosin and microtubule-kinesin sliding
velocity is effectively reduced or inhibited by body fluids
(blood components, cell lysates) unless diluted 100–200
times. This finding is expanded on in Figure 1 where we,
in addition to effects on velocity, also show concentration-
dependent effects of serum on the fraction of motile
filaments and on the fraction of independent experiments
where actomyosin motility was observed. Different factors
are likely to contribute to the deleterious effects. In addition
to serum proteins such as gelsolin, directly depolymerising
the actin filaments [27], there may be binding of other
blood serum components to HMM or actin [22].
To overcome the deleterious effects of blood serum we
here report a process based on magnetic separation that
allows exchange of body fluids for optimized biological
buffers without a dilution step. This process is unique in
that it encompasses separation steps relying on both
antibody-antigen interactions, magnetic forces and the
specificity of the actomyosin bond. In this method
we used commercially available ferromagnetic metal
nanoparticles (MP) coated with a thin layer of carboxy
(COOH) functionalized carbon graphite. Following 1-(3-
Dimethylaminopropyl)-3-ethylcarbodimide hydrochloride
(EDC) and N-Hydroxysuccinimide (NHS) incubation to
create amine-reactive NHS ester groups on the MPs, the
particles were linked to primary amines on the antibodies
(Figure 2(a)). Actin filaments with covalently attached
antibodies were obtained [15] using hetero-bifunctional
cross-linkers (Figure 2(b)). The separation workflow (see
also Methods) is illustrated in Figure 3. First, MPs (< 50
nm diameter) conjugated with polyclonal anti-rabbit IgG
(a-rIgG) antibodies were used to harvest the model analyte
(rabbit-IgG;rIgG) from serum (Figure 3:I) followed by
magnetic separation and exchange for a standard motility
buffer (Figure 3:II). The MPs with antibody-antigen
complexes were then (Figure 3:III) mixed with Alexa-488
phalloidin (APh) labeled actin filaments, conjugated with
polyclonal a-rIgG [15]. Next, a 30 min incubation period
allowed formation of antibody-analyte-actin complexes
e.g. actin-(a-rIgG)-(rIgG)-(a-rIgG)-MP aggregates. This
was possible in our experiments due to the polyclonality of
the a-rIgG antibody. Following an additional magnetic sep-
aration step the aggregates were enriched and transferred
to a flow cell (simulating a diagnostic nanodevice) where
they were tethered to myosin motor fragments (heavy mer-
omyosin; HMM; Figure 3:IV). This final step relies on the
specific recognition of the actin filaments by the myosin
motor domains, thus adding specificity to the process.




Figure 1 Effects of serum on actomyosin motility with and without magnetic separation to remove serum components. Full symbols
and lines: with magnetic separation. One control experiment but at least twenty filaments for each velocity measurement. Dashed symbols and
lines: without magnetic separation. Number of independent experiments in parentheses. Fraction of motile filaments (red; left vertical axis),
average sliding velocity (blue; right vertical axis) and the fraction of experimental occasions with any motility at all (black) when the flow cells
were directly incubated with blood serum at different dilutions. Sliding velocity (blue dashed line and open circles; data adapted from [22]).
Error bars show SEM.
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findings that the fraction of motile filaments and the
velocities of HMM propelled actin filaments in the
presence of 1 mM MgATP, were independent of the serum
concentration during the initial incubation step (Figure 1,
full lines; see further below). The number of filaments,
that were transferred to the flow cell (Figure 4(a)) and
that bound to HMM in the final step in Figure 3, was
significantly higher (p = 0.048) in the presence of rIgG
(60 nM) in the serum incubation step (378 ± 123 per
image frame, n = 3 flow cells) than in its absence (31 ± 8
per image frame, n = 3). Moreover, a similar fraction of
motile filaments (40–50%; Figure 4(a), red bars) and similar
velocities (not shown) were seen in the absence and
presence of rIgG pre-incubation. We attribute these data
(Figure 4(a) and 4(b)) to: (i) enrichment of actin filaments
in the second magnetic separation process (step III in
Figure 3) indicating cross-linking of actin filaments to
MPs via rIgG, (ii) effective binding of the aggregates to the
HMM coated surface and (iii) lack of motility inhibition
by MPs (as motility quality was not altered after the
magnetic separation steps). The lower total number of
observed filaments in 10 and 100% serum in Figure 4(a),
compared to more extensive serum dilutions, is consistent
with inhibiting effects of serum on the binding between
a-rIgG and rIgG. Such effects are expected for a multiplicity
of reasons [28] e.g. non-specific binding of other proteins
to the antibodies.The above results were confirmed in two additional
independent experiments (using different batches of
conjugated actin and conjugated MPs with rIgG as
antigen). In these experiments an incubation step with
bovine serum albumin was introduced just before addition
of actin filaments (see Methods). However, this did not
cause any apparent changes in the results compared to
those in Figure 4. Therefore data from all experiments in
buffer and 100% serum (with and without antigen) were
pooled from the two sets of experiments. The results
from these pooled experiments are summarized in
Table 1. In accordance with the results in Figure 4,
there was no significant difference in velocity and
fraction of motile filaments between the optimized
biological buffer, the serum sample without antigen
and the serum sample with antigen. However, the
presence of antigen during the incubation led to a
statistically significant increase in the number of
HMM-bound filaments, in step IV in Figure 3. Similar
results were obtained whether the filament number was
obtained by direct counting or if the relative filament
density under different conditions was estimated from
total background-subtracted fluorescence intensity
(Table 1). Whereas the latter method exhibited in-
creased variability it was considerably faster. The re-
sults in Table 1 are also fully consistent with results
using Rhodamine-labelled rIgG (Rh-rIgG) as antigen
(Additional file 1: Figure S1).
Figure 2 Schematic representations of the conjugation reactions. (a) Preparation of anti rabbit IgG coupled magnetic nano particle. Carboxy
(COOH) functionalized magnetic nanoparticles are activated with EDC and NHS. Amine-reactive NHS ester on the magnetic nanoparticle reacts
with primary amines on the antibody to yield anti rabbit IgG coupled magnetic nano particle. (b) Schematic representation of the conjugation
reaction between F-actin and anti rabbit IgG using heterobifunctional cross-linkers. F-actin is modified with C6-succinimidyl 6-hydrazinonicotinate
acetone hydrazone (C6-SANH) via primary amines on actin which then forms a biz-aryl-hydrazone bond with C6-succinimidyl 4-formylbenzoate
(C6-SFB) attached to anti rabit IgG via primary amines.
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experiments in Figure 1, 4 and Table 1 is due to (i)
omission of the incubation step with blocking actin
(non-fluorescent actin at 1 μM concentration) often used
to block ATP-insensitive myosin heads, and (ii) omission of
a step with actin affinity separation by ultracentrifugation
(to remove the ATP-insensitive heads) prior to the
motility assay. The first of these omissions was important
in order to leave as many myosin heads as possible free to
bind actin filaments.
There was a tendency for a particularly low fraction of
motile filaments in step IV (Figure 3) in absence of antigen
in the sample solution (lower row, Table 1). The basis
for this finding can be sought in the very low number of
short actin filaments (Figure 4b) under these conditions.
Whereas, the low number is due to lack of cross-linking
of actin filaments to MPs in the absence of antigen, we
attribute the fragmentation of the filaments to shearing
forces e.g. related to repeated mixing and pipetting. The
short filaments detach from the surface with higher
probability than long filaments but only if they are motile
and not if they are bound to rigor-like ATP-insensitiveheads. This leads to an appreciable effect on the fraction
of motile filaments particularly when the total number of
filaments is low as was the case in the initial absence of
antigen.
For increased specific cross-linking efficiency between
MPs and actin filaments we attempted to use magnetic
microparticles (average size 1 μm, according to manufac-
turer) instead of nanoparticles. However, due to the high
binding capacity of the larger particles there was an
appreciable tendency for formation of large aggregates
composed of both filaments and microparticles (Additional
file 1: Figure S2). These large aggregates may be potentially
useful for magnetic concentration of actin-MP aggregates
but are clearly not useful in separation schemes where
actomyosin driven transport is required, e.g. for motor
driven concentration [7,29], subsequent to the magnetic
pre-separation. In this case, nanoparticles must be used.
Their considerably smaller surface area (although not
smaller surface/volume ratio) make them less sticky
consistent with the findings that actomyosin driven
motility is less affected by large than small nanoscale
cargoes [30]. Furthermore, the small size of nanoparticles
Antigen Antibody Magnet Myosin MP Serum ActinBuffer 
Step I II III IV 
Figure 3 Principle for magnetic pre-concentration procedure. Whereas the antibody in the present study was anti-rabbit IgG and the
antigen, rabbit IgG, the terms “antibody” and “antigen” are used to illustrate the generality of the approach. In step I, antigens are captured from
serum by the antibodies conjugated to magnetic particles, MPs. Antigen-antibody-MP complexes are then concentrated using an external
magnet to a small volume in the eppendorf tube while simultaneously exchanging serum for an optimized biological buffer (step II). Actin
filaments conjugated with antibodies are then added and a second magnetic concentration step is performed (step III). This step is expected to
leave actin filaments without MPs in the supernatant (that is removed) and those that have cross-linked MPs in the pellet. The latter are re-
dispersed in buffer B and added to a flow cell (step IV) with surfaces coated with heavy meromyosin motor fragments for specific binding of
actin filaments (e.g. actin-antibody-antigen-antibody-MP complexes as illustrated) and molecular motor driven transportation.
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of the type that we have generally used to guide HMM
propelled actin filaments. The increase in the number of
actin filaments on the surface (Figure 4, Table 1) at the
end of the procedure in Figure 3, in itself, reports the
presence of analyte whether the filaments are cross-linked
to MPs or not. Just by counting the number of actin
filaments or measure the increase in fluorescence
intensity due to actin filament binding to HMM on
the surface we could detect the presence of analyte in
the 10–100 nM concentration range (Additional file 1:
Figure S1). This is in the relevant range for several
clinically important disease markers, e.g. the inflammation
marker C-reactive protein (CRP) [33]. However, while
detection of 50–60 nM antigens gave consistent results
between experiments in terms of the number of observed
filaments in step IV of Figure 3, attempts to consistently
detect antigen at lower concentration (0.5 - 5 nM) was
unsuccessful (Additional file 1: Figure S1) as further
discussed below.
To summarize, we have demonstrated a conceptually
useful approach for capturing analytes from serum for
subsequent motor driven separation/detection. The
usefulness of the method was clear from the consistent
signal in the final step in Figure 3 (corresponding to a
certain number of actin filaments) for a sample antigen
concentration of 50–60 nM. However, clearly, our results
also suggest that there is appreciable room for improve-
ment. In order to understand complicating factors to
facilitate future optimizations, we used a combined micro-
scopic and fluorescence spectroscopic approach to analyze
the different steps in the procedure in Figure 3.
First, of critical importance is insight into the effectiveness
of the selective removal of serum components in step IIin Figure 3. This step was monitored by measuring the
tryptophan fluorescence (Figure 5a) from the supernatants
after magnetic pelleting. As exemplified in Figure 5a
(similar in one further experiment) there was < 1%
serum proteins left in the supernatant after a first washing
sub-step (within step II) as indicated by the tryptophan
fluorescence. Here, we studied the supernatant rather than
the MP-containing pellet due to disturbing effects of the
MPs on the fluorescence signal. Altogether, two further
washes, each associated with magnetic pelleting and
exchange of supernatant, in step II, ensured that negligible
amounts of serum proteins (<0.1% ) remained when the
MP-Ab-Ag conjugates were mixed with the antibody-
conjugated actin filaments in the next step (step III in
Figure 3). This finding is consistent with the observation
(Figure 1) of maintained actomyosin function after the
entire procedure in Figure 3. However, the spectroscopic
data show that the removal of serum in step II is actually
appreciably more effective than can be inferred from the
lack of effects on motility. Indeed, already the degree of
serum removal seen after one magnetically assisted
washing step would be sufficient [22] to account for the
finding that motility was unaffected (Figure 1). The very
effective serum removal has important implications.
First, it makes it very unlikely that actin binding proteins
in serum [27], e.g. the severing protein gelsolin contribute
to the observation of small, apparently fragmented
filaments in the final step in Figure 3. Instead, we
attribute the latter observation to shear forces that affect
the filaments during repeated pipetting, mixing and,
possibly, the magnetic separation itself (Figure 3, step III;
Additional file 1: Figure S3). Second, the finding of very
effective serum removal suggests that 1–2 washes would
be sufficient in steps II and III rather than 3 and 5 washes,
a b
With Antigen Without Antigen
Figure 4 Effects of magnetic pre-concentration and removal of serum. (a) The total number of filaments (grey bars) and the number of
motile filaments (red bars) at the end of the procedure in Figure 3 for different concentrations of blood serum (0 – 100%) and in the presence
(+) and absence (−) of antigen (r-IgG) in step I in Figure 3. (b) Fluorescent images from the experiment in (a) with or without antigen. In the
presence of antigen (rIgG) several fluorescent filaments can be seen suggesting crosslinking between arIgG antibodies conjugate on actin and
MPs via the antigen. In the absence of antigen only a few filaments are bound to HMM on the surface. Both images are from samples with 100%
serum. Scale bar 10 μm.
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effect to reduce shearing forces on the actin filaments.
For further optimization, it is of interest to know to
what extent that antigens are actually captured by the
antibody-conjugated MPs in step I of the procedure in
Figure 3. First, in order to quantify the number of
antibodies per MP in the reaction in Figure 2a we
measured (Figure 5b) the intrinsic protein fluorescence
prior to, and after coupling. The decrease in the antibody
concentration in the MP-free solution suggested by these
measurements indicated antibody coupling corresponding
to about 40 antibodies per MP i.e. an antibody concentra-
tion of 1.2 μM assuming a MP concentration of about 30
nM in step I of the procedure in Figure 3.
Most likely, (cf. [34]) the concentration of antibodies with
antigen binding capacity (i.e. those that are appropriately
oriented and in native state) was considerably lower.
Additionally the degree of antigen binding is likely to be
reduced if aggregates of MPs are quickly formed via
antibody-antigen links. The formation of such links is
possible with the polyclonal antibodies that we used
here. This effect would be particularly severe at low
concentrations of antigen where only a small fraction of
the antibodies on the MPs are occupied, leaving a large
number of them available for cross-linking to other anti-
body conjugated MPs. This effect, illustrated in AdditionalTable 1 Effect of antigen (Ag) on number of actin filaments, f
final stage of the magnetic separation procedure in Figure 3
Sample Velocity (μm s-1)
Buffer B with Ag (n = 3) 6.44 ± 0.48
Serum (100%) with Ag (n = 3) 5.86 ± 0.44
Serum(100%) without Ag (n = 3) 6.26 ± 0.71
*p < 0.05; 1 p = 0.0256, 2 p = 0.0281 (normalized). AU: normalized arbitrary units.
Sample composed of buffer B or 100% serum with (50-60 nM) or without rIgG (Ag)
error of the mean from three independent experiments for each condition. Intensit
were used in the different experiments. Repeated measures one-way Analysis of Vafile 1: Figure S4, would also cause appreciably reduced
cross-linking between MPs and antibody conjugated actin
filaments when the antigen concentration is low relative
to the concentration of antibody-conjugated MPs. The
reason is that majority of the antigens, under these
conditions, would be hidden inside MP-MP aggregates as
indicated in Additional file 1: Figure S4. This is in good
agreement with the lack of consistent detection of antigen
at concentrations of 5 nM or less. That MP-antigen aggre-
gates did really form was demonstrated by direct micro-
scopic observation (Figure 6). Thus, after performing step
I (50 nM antigen, 10 min) in Figure 3 we took out a
sample that was infused into a flow cell placed on a
magnet (the one used for magnetic separation) during a 30
s incubation period. Now, using dark-field and fluorescence
microscopy we observed several, micrometer sized
aggregates that we attribute to magnetic particles with
captured Rh-rIgG molecules.
We also searched for similar aggregates in step IV
(Figure 3), i.e. after completion of the entire procedure but
very few were observed (data not shown) in spite of a large
number of actin filaments compared to the control situ-
ation. Provided that all MPs could be detected by the
combined dark-field and fluorescence microscopy, this
suggests that very few MPs are required for an appreciably
increased number of actin filaments in step IV.luorescence intensity and actomyosin motility quality in
Fraction Motile # of filaments Intensity (AU)
0.51 ± 0.03 628 ± 38 0.89 ± 0.11
0.38 ± 0.05 523 ± 164 0.81 ± 0.11
0.27 ± 0.08 27 ± 11*1 0.22 ± 0.07*2
was added at the first stage of this procedure. Data given as mean ± standard
y values are given as normalized arbitrary units since different fluorophores





















































Figure 5 Fluorescence spectroscopic monitoring of the separation process. (a) Tryptophan fluorescence from the supernatants during
different magnetic washes in step II (Figure 3) where serum is removed. MPs and bound antigens are pelleted with an external magnet while
serum is removed (red full line). The pellet is then resuspended in 1 ml buffer A and then pelleted again while the supernatant was removed
(green full line). This washing procedure was repeated two more times (blue full line). Dashed lines show (for reference) dilutions of serum to
10% (red), 1% (green) and 0.1% (blue). (b) Tryptophan fluorescence from the solution before and after the conjugation between MPs and
antibodies. Red line: emission from antibody sample before magnetic particles were added. Blue line: emission from the supernatant after
conjugation reaction where magnetic particles and bound antibodies are pelleted using a magnet.
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actin filaments at 50 nM antigen, is strong support of
the usefulness of the described approach. Furthermore,
it would be trivial to substitute polyclonal antibodies
with monoclonal antibodies in a real device thereby
eliminating complexities due to MP-MP aggregate
formation. In the case with monoclonal antibodies,
those on the magnetic particles would be directed
against another epitope of the antigen than those on
the actin filaments. In addition to increased sensitivity,
this approach would also increase the specificity due to
the involvement of two different specific antibodies in
creating the diagnostically relevant link between magnetic
particle and actin filament.
Sensitivity and detection rate should be possible to
increase further by substituting filament counting and
whole frame intensity measurements by an automatedprocess whereby a concentrator device [7,29] concentrates
the motile actin filaments in a nanoscale detector area.
This would give a measure of the fluorescence intensity
attributed to HMM propelled actin filaments insensitive
to e.g. changes in background fluorescence or altered
illumination conditions that may severely affect the
full-frame fluorescence intensity [35]. Moreover, the
concentration approach is automated and fast compared
to the manual filament counting procedure.
A third modification of the procedure that is likely to
cause significant improvements, both with regard to
limit of detection and specificity, would be the use of
magnetic forces to pull actin-MP aggregates to the surface
in the final step in Figure 3. In this case, only those actin
filaments that are linked to MPs would be pulled by the
magnetic field whereas only those MPs that are bound to
an actin filament would be specifically linked to the
Dark Field (MP)
a b c d
TRITC (Ag) FITC (Actin) Merged
Figure 6 Aggregation of magnetic microparticles observed on a flow-cell surface pre-incubated with HMM and a-rIgG conjugated
actin filaments (after step I in Figure 3). (a) Dark field microscopy where bright spots are believed to represent MPs or aggregates of several
MPs. (b) Fluorescence micrograph using TRITC filter set to visualize Rh-rIgG (c) Fluorescence micrograph using FITC filter set to visualize APh
labeled actin filaments. (d) Merge of (a)-(c) with dark-field images red, Rh-rIgG (TRITC) green and actin filaments (APh) blue. Scale bar 10 μm.
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height should be increased, from the current value of
0.1 mm, in order to increase the volume from which
actin-MP aggregates are recruited and increase the ratio
of magnetically driven to diffusional transport.
As indicated above, the procedure in Figure 3 would
be readily interfaced with a molecular motor driven
concentrator device [29,36] for additional 100–1000 fold
signal amplification. Finally, we have presented evidence
that the number of rinsing steps may be appreciably
reduced. Also the incubation times may be reduced.
For instance only 10 min incubation period was used
in a recent immunoassay [24] for binding of analyte at
attomolar concentration to magnetic microparticles in
solution. However, optimizations of the detailed assay
procedure would require a large number of time consuming
tests. These would not add much of conceptual interest
and are therefore outside the scope of the present study.Conclusions
We have described a novel approach for capturing
analytes from serum by antibody conjugated magnetic
particles adapted for use in molecular motor driven
concentrator devices [7,29]. Importantly, this method
eliminates the recently discovered [22] deleterious effects
of serum on the actin filaments and on actomyosin motor
function. Subsequent to the analyte capture, magnetic
separation thus allows exchange of body fluids (e.g. blood
serum) for an optimized biological buffer and subsequent
mixing with antibody-conjugated actin filaments. Now,
large aggregates tend to form between actin filaments and
micrometer sized antibody coated particles, opening for
conventional magnetic concentration of aggregates between
actin filaments and magnetic particles. On the other hand,
magnetic nanoparticles form smaller aggregates with actin
filaments that may be transported by heavy meromyosin
motor fragments. Pending optimizations, particularly the
use of monoclonal antibodies as suggested by our analysis




Magnetic nanoparticles (MPs) with mean diameter of
30 nm (according to manufacturer) and surface-coated
with primary carboxylic groups was purchased from
TurboBeads (Zurich, Switzerland). C6-succinimidyl 6-
hydrazinonicotinate acetone hydrazone (C6-SANH) and
C6-succinimidyl 4-formylbenzoate (C6-SFB) were pur-
chased from Solulink, San Diego, CA, USA. Anti-rabbit
IgG (H&L, Goat, a-rIgG) was purchased from Rockland
Immunochemicals, Gilbertsville, USA. Zeba desalt spin
columns and bicinchoninic acid (BCA) protein assay kits
were purchased from Pierce Rockford, IL, USA. Rabbit
IgG (rIgG) and all other chemicals were of analytical
grade and, unless otherwise stated, purchased from
Sigma-Aldrich Sweden AB, Stockholm, Sweden.
Preparation of muscle proteins
Actin was prepared from rabbit skeletal muscle [37] and
actin filaments were fluorescently labeled with Alexa-488
phalloidin (APh) (Molecular Probes Invitrogen, Eugene,
OR) [32,38,39]. Myosin II was purified from rabbit fast
skeletal muscle and heavy meromyosin (HMM) was
prepared by digestion of myosin with α-chymotrypsin
[38,40]. All experiments using animal material were
performed in accordance with national and EU-legislation
and were approved by the Regional Ethical Committee for
Animal experiments (reference # 96–11), Linköping,
Sweden.
Activation and coupling of magnetic nanoparticles
Magnetic nanoparticles (30 mg mL-1 corresponding to
83 nM; according to manufacturer´s specifications) were
dispersed by sonication in an ultrasonic bath for 15
minutes, then collected using a magnet (Neodymium
Magnet, 14 × 8 mm, pulling strength 5 ± 0,5 kg. Svenska
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with 1 mL of activation buffer (54 mM (2-(N-morpholino)
ethanesulfonic acid (MES), pH 5.5). These steps were
repeated three times. One mL of MP solution (30 mg mL-1
in activation buffer) was mixed with 1 mL of activation
solution (10 mg EDC and 10 mg NHS dissolved in 1 mL
activation buffer) and incubated for 20 min at room
temperature (RT) on a shaker. The activated MPs were
collected using the magnet and the supernatant was
discarded. One mg of a-rIgG was mixed with 1 mL of
the activated MPs in activation buffer and incubated for
30 minutes at RT on a shaker. This was followed by
washing four times with 1 mL of PBST (10 mM sodium
phosphate, 0.15 M NaCl with 0.5% Tween-20, pH 7.4)
and finally two times with 1 mL of buffer A (1 mM
MgCl2, 10 mM 3-morpholinopropane-1-sulfonic acid
(MOPS), 0.1 mM K2-ethylene glycol tetraacetic acid
(EGTA), pH 7.4). The a-rIgG-conjugated MPs were then
mixed with 1 mL of storage buffer (buffer A with 0.05%
sodium azide) and stored at 4°C over night.
Preparation of anti-rabbit IgG conjugated actin filaments
F-actin, conjugated with a-rIgG was prepared essentially
as described previously [15]. First, F-actin (3.5 mg mL-1
in modification buffer 1; 100 mM (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) (HEPES), 150 mM KCl,
5 mM MgCl2, 1 mM Na2ATP, pH 8.0) was incubated with
C6-SANH linker (dissolved in Dimethyl sulfoxide, DMSO)
at RT for 2 h with a molar ratio of 1:2 (actin:linker). Excess
linker was removed using ultracentrifugation (Beckman-
Optimamax-XP ultracentrifuge, 100,000 g, 4°C, 25 min)
through a 10% glycerol cushion. Pellets were re-suspended
in modification buffer 1 with 5% glycerol cushion. A sec-
ond ultracentrifugation step was applied with subse-
quent re-suspension in conjugation buffer (100 mM
MES, 150 mM KCl, 5 mM MgCl2, 1 mM Na2ATP, pH
6.0). The actin solutions were sonicated gently on ice to
disperse the filaments and these were then stored on
ice until the conjugation with a-rIgG. Our previous re-
sults [15] suggest that the covalent modification of actin
with the C6-SANH linker does not modify actin function.
The a-rIgG (2 mg mL-1 in PBS buffer; 0.1 M sodium
phosphate, 0.15 M NaCl, pH 7.4) solution was incubated
with 10-fold molar excess of C6-SFB linker (dissolved in
DMSO) at RT for 2 h. Modified a-rIgG was desalted using
zeba desalt spin column against conjugation buffer (see
above) to remove excess linker and to exchange buffer. The
modified antibodies were stored on ice until further use.
The C6-SANH modified F-actin sample was incubated
with C6-SFB modified a-rIgG solutions. Addition of 10
mM catalyst buffer from stock solution (100 mM aniline
in conjugation buffer) started the reaction that was
allowed to proceed for 6 h at RT. The molar ratio of
modified F-actin and modified a-rIgG was 2:1 respectively.In order to remove catalyst and exchange the buffer,
samples were dialyzed at 4°C against G-actin buffer
(2 mM Tris base, pH 8.5, 0.2 mM Na2ATP, 0.5 mM
dithiothreitol (DTT), 0.2 mM CaCl2, 3 mM NaN3). For
long-term storage, samples were flash frozen in liquid
nitrogen and stored at −80°C.
The conjugated G-actin monomers (actin-a-rIgG) were
co-polymerized with non-conjugated monomers to form
filaments with 1:3 molar ratio of conjugated to non-
conjugated actin. The co-polymerization reaction was
performed at 4°C (3 h) by addition of KCl, MgCl2 and
ATP to final concentrations of 100 mM, 2 mM and 3.3
mM, respectively. The co-polymer was fluorescence-labeled
with APh or RhPh (molar ratio: 1:1.5; actin:APh or RhPh)
at 4°C over night (see above).
Magnetic capture of analytes from serum
Figure 3 illustrates the principle for magnetic capture of
antigen from blood and the subsequent separation from
other serum components and integration with the
actomyosin motor system. Serum was first obtained
from human blood drawn into Vacutainer™ glass tubes.
The blood was from volunteers who consented to the
procedures under a protocol approved by the regional
ethical committee in Linköping, Sweden. After 1 h at RT
the sample was centrifuged (3000 g for 20 minutes at RT;
20°C) to remove blood cells and solidified fibrin thus
giving blood serum. Three different concentrations of
serum were prepared by dilution in buffer B (buffer A with
1 mM DTT and 50 mM KCl): 100%, 10% and 1%. For the
subsequent magnetic separation process the different
serum samples were aliquoted into six (two for each
concentration), tubes (200 μl per tube). Magnetic particles
conjugated with a-rIgG were added to all six tubes (2.5
mg magnetic particles per tube).
One additional tube contained 0% serum (100% buffer
B). The rIgG (60 nM) was added to four of the vials
(100%, 10%, 1% and 0%) and all seven tubes were put on
a shaker for 1 h at RT. Samples were then washed 10 times
each with 500 μl of buffer B while applying magnetic
forces to keep magnetic particles and their bound analytes
(rIgG) in the tubes. This allowed removal of serum and
exchange for optimized biological buffer (buffer B). Each
tube was then incubated with 250 nM a-rIgG conjugated
actin filaments (final volume 250 μl) for 1 h at RT on a
shaker in the dark followed by gentle wash 10 times in
buffer B under magnetic separation forces. Finally 250 μl
of buffer B was added to the tube before the content was
infused into a motility assay flow cell.
In another set of experiments, 2.5 mg MP-a-rIgG was
mixed with 100% Serum and 0% Serum with 50 nM of
rIgG for 30 min at RT on a shaker in the test samples.
Alternatively, 0.5-50 nM Rh-rIgG was used as antigen.
Control samples were treated similarly but were without
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washed three times with 1 mL of PBST (not used with
Rh-rIgG) and three times with 1 mL of buffer A, while
applying magnetic forces to keep magnetic particles and
bound analytes (rIgG) in the tubes. This was expected to
allow effective removal of serum components. Subsequently,
300 μL of 1% bovine serum albumin (BSA) was added to
each tube followed by 30 min incubation at RT under
gentle shaking. This step when used (not with Rh-rIgG)
was followed by two times wash with 1 mL of buffer A.
Each tube was then incubated with 250 nM a-rIgG conju-
gated filaments for 30 min at RT on a shaker in the dark.
Samples were then washed gently seven times (five times
with Rh-rIgG) in buffer B under magnetic pelleting of
complexes with magnetic particles, e.g. MP-a-rIgG-rIgG-
a-rIgG-actin and final addition of 250 μl buffer B to
re-disperse the pellet (see above).In vitro motility assays (IVMA)
Flow cells were constructed from two cover-slips with
double-sided sticky tape as spacers. The motility supporting
surface (bottom of flow cell) was derivatized with
trimethylchlorosilane (TMCS) as described previously
[41]. All solutions that were added to the flow cell were
based on buffer A (see above) and all proteins were
diluted in buffer B (see above). The flow cell was pre-
incubated according to standard procedures [15,39,42]: (i)
HMM (120 μg mL-1) for 2 min, (ii) 1 mg mL-1 BSA for
30 s (iii) wash with buffer B and (iv) addition of re-
dispersed pellet from the magnetic separation (described
above). After an incubation period of 3 min, flow cells
were washed with buffer B, and (vi) incubated with r60
assay solution (buffer A with 10 mM DTT, 35 mM KCl,
ionic strength 60 mM). The r60 solution was also sup-
plied with an anti-bleach system (final activity concen-
trations of 3 mg mL-1 glucose, 20 U mL-1 glucose
oxidase and 870 U mL-1 catalase). Finally, (vii) a60 assay
solution was added to the flow cell to induce filament
sliding. The a60 solution was similar to the r60 solution
but with addition of 1 mM MgATP and an ATP regen-
erating system (2.5 mM creatine phosphate and 3.5 U
mL-1 creatine phosphokinase).Fluorescence spectroscopy
Fluorescence spectroscopy was performed using a FluoroLog
FL3-22 Spectrophotometer (Instruments S.A Inc. New
Jersey, USA). For estimation of changes in antibody and
serum protein concentrations, we used an excitation
wavelength of 295 nm (slit 2 nm) and read emission in the
range from 310 nm to 400 nm (slit 6 nm). Antigens
labeled with rhodamin (~2 rhodamin per antibody) were
studied using an excitation wavelength of 555 nm (slit 3)
and emission was read at 570–700 nm (slit 5 nm).Microscopy
Fluorescently labeled actin filaments were observed using a
Nikon Eclipse TE300 inverted fluorescence microscope
(Nikon Corp., Tokyo, Japan) equipped with a temperature-
regulated Nikon (100 × 1.4 NA) oil immersion objective,
TRITC (Ex. 540/25, DM 565, and BA 605/25) and FITC
(Ex. 465–495, DM 505, and BA 515–555) filter sets. Image
sequences were recorded using a cooled Hammamtsu
EMCCD camera as described previously [32]. Actin
velocities were measured using a manual tracking pro-
gram developed in a Matlab enviroment (The MathWorks
Inc, Natick, MA) [43,44]. The number of actin filaments
and the total intensities of the different frames were
measured using Image J (Rasband, W.S., ImageJ, U. S.
National Institutes of Health, Bethesda, Maryland, USA,
http://imagej.nih.gov/ij/, 1997–2012.).
Dark field microscopy was performed using a Nikon oil
immersion dark field condenser together with a Nikon oil
immersion objective (100 ×, 0.5-1.3 NA). The latter was
also used for fluorescence microscopy in Figure 6.
Statistical and related analysis
Statistical analyses were implemented in GraphPad Prism
(v. 6.01; GraphPad Software, San Diego, CA). Unless
otherwise stated, data are given as mean ± standard
error of the mean (SEM) and statistical hypothesis
testing was performed using two-tailed t-test (paired
when appropriate) or repeated measures ANOVA.
Images from the individual experiments were analyzed
manually by counting the number of filaments in one
frame from each flow cell. These filaments were then
categorized into stationary or motile by observation in
25 frames (5 seconds of real time). To verify the manual
counting method the average background-subtracted
intensity from 50 consecutive image frames of stationary
filaments was also obtained and used as an alternative
measure of the relative number of filaments. Average
background pixel intensity was calculated as the mean
pixel intensity value in four filament-free areas, one in
each quadrant, of the averaged intensity image.
Additional file
Additional file 1: Figures S1-S4. Figure S1 shows titrations where
the number of HMM bound actin filaments (step IV, Figure 3) is
shown as a function of antigen concentration (0.5-50 nM). Figure. S2
shows a fluorescent micrograph illustrating aggregation of magnetic
microparticles. Figure S3 and Figure S4 show schematic illustrations
of filament fragmentation (S3) and magnetic nanoparticle
aggregation (S4).
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